<DOC>
	<DOCNO>NCT00002347</DOCNO>
	<brief_summary>To evaluate tolerance immunologic virologic effect multidrug combination antiretrovirals patient HIV infection . Specifically , evaluate zidovudine/zalcitabine ( AZT / ddC ) alone combination either nevirapine saquinavir ( Ro 31-8959 ) . Administration three-drug combination treatment HIV infection prefer monotherapy duotherapy . A system design rapidly evaluate current multidrug combination antiretrovirals allow addition new agent become available .</brief_summary>
	<brief_title>The Safety Effectiveness Retrovir Plus HIVID Combined With Either Nevirapine Invirase Treatment HIV Infection</brief_title>
	<detailed_description>Administration three-drug combination treatment HIV infection prefer monotherapy duotherapy . A system design rapidly evaluate current multidrug combination antiretrovirals allow addition new agent become available . Patients randomize receive AZT/ddC either alone combination nevirapine Ro 31-8959 minimum 48 week . Patients follow week 2 4 every 4 week thereafter .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Encouraged : PCP chemoprophylaxis patient whose CD4 count fall 200 cells/mm3 develop PCP study . Allowed : Secondary prophylaxis nonexperimental agent patient develop TB , Mycobacterium aviumintracellulare , toxoplasmosis , histoplasmosis , cryptococcosis , disseminate candidiasis , cytomegalovirus infection . Acyclovir 21 day less acute treatment . Recombinant erythropoietin GCSF grade 3 bad anemia neutropenia , respectively . Patients must : HIV infection . CD4 count 200 500 cells/mm3 . No prior antiretroviral therapy . Life expectancy least 48 week . Consent parent guardian le 18 year age . NOTE : Participating center encourage enroll female patient . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Any grade 3 great toxicity . Symptoms peripheral neuropathy . Malabsorption severe chronic diarrhea . Inability eat least one meal daily chronic nausea , emesis , abdominal esophageal discomfort . Concurrent Medication : Excluded first 28 day nevirapine administration : Augmentin antibiotic contain clavulanic acid . Excluded time : Dicumarol , warfarin , anticoagulant medication . Tolbutamide . Cimetidine . Erythromycin . Patients follow prior condition exclude : History acute chronic pancreatitis . History grade 2 bad peripheral neuropathy cause . Prior Medication : Excluded : Any prior antiretroviral therapy . Excluded within 4 week prior study entry : Immunomodulating agent systemic corticosteroid , IL2 , alphainterferon , betainterferon , gammainterferon . Immunotherapeutic vaccine . Cytotoxic chemotherapy . Erythromycin . Dicumarol , Coumadin / warfarin , anticoagulant medication . Phenobarbital . Amoxicillin / clavulanate . Ticarcillin / clavulanate . Tolbutamide . Erythromycin . Cimetidine . Prior Treatment : Excluded within 4 week prior study entry : Nonlocal radiation therapy . Current alcohol illicit drug use would interfere ability comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1995</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Saquinavir</keyword>
</DOC>